We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

126 hedge funds and large institutions have $53.8M invested in Lineage Cell Therapeutics in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 38 increasing their positions, 16 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 16

115% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 13

11% more funds holding

Funds holding: 114 → 126 (+12)

1.48% less ownership

Funds ownership: 50.08% → 48.6% (-1.5%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

37% less capital invested

Capital invested by funds: $85.6M → $53.8M (-$31.8M)

Holders
126
Holders Change
+12
Holders Change %
+10.53%
% of All Funds
1.66%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
28
Increased
38
Reduced
16
Closed
13
Calls
$37K
Puts
–
Net Calls
+$37K
Net Calls Change
-$20K

Top Buyers

1
PA
Perceptive Advisors
New York
+$5.31M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$2.9M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.53M
4
DCM
DAFNA Capital Management
California
+$852K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$759K

Top Sellers

1
LGM
Logos Global Management
California
-$4.53M
2
Bank of America
Bank of America
North Carolina
-$980K
3
MCM
MAI Capital Management
Ohio
-$747K
4
BCM
Bridgeway Capital Management
Texas
-$249K
5
LFCM
Long Focus Capital Management
Puerto Rico
-$195K
Name Holding Trade Value Shares
Change 		Change in
Stake
New York State Common Retirement Fund
101
New York State Common Retirement Fund
New York
$1.67K – – –
AFG
102
Albion Financial Group
Utah
$1.53K – – –
PP
103
Pacifica Partners
Canada
$1.51K – – –
AG
104
AmeriFlex Group
Nevada
$1.32K +$1.61K +2,200 New
API
105
Asset Planning Inc
California
$1.02K +$1.5K +2,036 New
Carson Wealth (CWM LLC)
106
Carson Wealth (CWM LLC)
Nebraska
$1K -$388 -528 -23%
RDIA
107
RE Dickinson Investment Advisors
Iowa
$1K +$151 +205 New
TCOV
108
Trust Company of Vermont
Vermont
$780 – – –
Nisa Investment Advisors
109
Nisa Investment Advisors
Missouri
$750 +$916 +1,248 +509%
National Bank of Canada
110
National Bank of Canada
Quebec, Canada
$629 +$907 +1,236 +8,829%
SMAM
111
Sugar Maple Asset Management
Wisconsin
$503 +$734 +1,000 New
RAM
112
Riggs Asset Management
Pennsylvania
$496 – – –
Jones Financial Companies
113
Jones Financial Companies
Missouri
$351 +$514 +700 New
AWM
114
Avior Wealth Management
Nebraska
$150 – – –
SCM
115
Sterling Capital Management
North Carolina
$75 – – –
SIS
116
Strategic Investment Solutions
Illinois
$48 – – –
CAS
117
Coppell Advisory Solutions
Texas
$31 – – –
FWM
118
FLP Wealth Management
Arkansas
$25 +$37 +50 New
LC
119
Lindbrook Capital
California
$15 – – –
PNC Financial Services Group
120
PNC Financial Services Group
Pennsylvania
$4 +$6 +8 New
IA
121
IFP Advisors
Florida
$2 +$2 +3 New
DJSG
122
D.J. St. Germain
Massachusetts
$1 – – –
PMFA
123
Plante Moran Financial Advisors
Michigan
$1 – – –
LGM
124
Logos Global Management
California
– -$4.53M -5,000,000 Closed
LFCM
125
Long Focus Capital Management
Puerto Rico
– -$195K -215,000 Closed
2 3 4
5
6

LCTX Hedge Fund Activity: Q4 2024 in Review

126 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2024, worth a combined $53.8M — down 37% from $85.6M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new LCTX positions and 13 closed out — a net gain of 15 holders — while 38 added to existing stakes and 16 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $5.31M. The largest seller was Logos Global Management, exiting entirely with an estimated $4.53M sold.

  • 126 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2024, up from 114 in Q3 2024.
  • Funds reported $53.8M of Lineage Cell Therapeutics stock for Q4 2024, down 37% quarter-over-quarter.
  • 28 funds opened new Lineage Cell Therapeutics positions in Q4 2024 and 13 closed out, a net change of +15 holders.
  • The largest Lineage Cell Therapeutics buyer in Q4 2024 was Perceptive Advisors, an estimated $5.31M added.
  • The largest Lineage Cell Therapeutics seller in Q4 2024 was Logos Global Management, an estimated $4.53M sold.

Based on aggregated 13F filings for Q4 2024.